At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 639 enrolled
Drug / intervention
IC51biological
Likely dose
IC51 6 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51. Double Blind, Randomized, Controlled Phase 3 Study.
In Brief
A Phase 3 clinical trial evaluating IC51 for Japanese Encephalitis. Completed, enrolled 639 participants.
Detailed Summary
The objective is to demonstrate equivalence of three IC51 batches in terms of Geometric Mean Titers for anti-JEV neutralizing antibody.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJapanese Encephalitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
Primary CompletionApr 2007
Study CompletionSep 2007
First PostedJan 2008
TodayJul 2026
First PostedJan 16, 2008
Enrollment StartSep 1, 2006
Primary CompletionApr 1, 2007
Study CompletionSep 1, 2007
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 18.5 years ago
Interventions
IC51biological
6 mcg, intramuscularly \[i.m.\], 0.5 mL